ARCHIVES

Pediatric Rule Makes FDA Consider Defining Tumors By Molecular Target.

This article is from The Cancer Letter archive.

Vol. 27 No. 31 | August 31, 2001

Download PDF Visit The Full Archive

Related Articles

First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma

February 22, 2013

Doroshow: NCI Leaves It Up to Groups To Make Their Own Merger Deals

February 11, 2011

In Brief: Cancer Program “Strengthened” NIH, Report From Biomedical Research Panel Contends

April 16, 1976

FDA Ponders Standards For “Retrospective Prospective” Studies

January 30, 2009

Cancer Letter Founder Receives ACCC Award, Stresses Importance Of Bypass Budget

March 20, 1992

NCAB Member Seeks Broder’s Resignation, Gets No support

June 3, 1994